MediciNova Operating Margin from 2010 to 2024
| MNOV Stock | USD 2.05 0.08 3.76% |
Check MediciNova financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MediciNova's main balance sheet or income statement drivers, such as Interest Expense of 679.1 K, Other Operating Expenses of 14.5 M or Research Development of 7.9 M, as well as many indicators such as Price To Sales Ratio of 107, Dividend Yield of 0.0 or PTB Ratio of 1.63. MediciNova financial statements analysis is a perfect complement when working with MediciNova Valuation or Volatility modules.
MediciNova | Operating Margin |
Latest MediciNova's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of MediciNova over the last few years. It is MediciNova's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MediciNova's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.82) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
MediciNova Operating Margin Regression Statistics
| Arithmetic Mean | (11.70) | |
| Coefficient Of Variation | (210.17) | |
| Mean Deviation | 12.18 | |
| Median | (2.53) | |
| Standard Deviation | 24.59 | |
| Sample Variance | 604.73 | |
| Range | 98.4822 | |
| R-Value | 0.43 | |
| Mean Square Error | 528.60 | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | 2.39 | |
| Total Sum of Squares | 8,466 |
MediciNova Operating Margin History
About MediciNova Financial Statements
MediciNova investors use historical fundamental indicators, such as MediciNova's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MediciNova. Please read more on our technical analysis and fundamental analysis pages.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. Medicinova operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.